Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Phase 1
21
about 18 years
≤21
1 site in TX
What this study is about
This trial is testing a new treatment called 21.15.GPC3-CAR T cells, which are genetically engineered T cells designed to target solid tumors with GPC3 protein. This treatment combines CAR technology with IL-15 and IL-21 genes to enhance the T cells' ability to kill cancer cells and stay in the body longer. It aims to determine if this new approach is safe and effective for adults with specific types of solid tumors.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take 21.15.GPC3-CAR T cells
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cell therapy (Engineered T-cells that target specific cancer antigens)
Primary: Number of Patients with Dose Limiting Toxicity
Oncology